List of Subjects in 17 CFR Part 230

Reporting and recordkeeping requirements, Securities.

Text of Rule and Form Proposals

For the reasons set out in the preamble, title 17, chapter II of the Code of Federal Regulations is proposed to be amended as follows:

PART 230—GENERAL RULES AND REGULATIONS, SECURITIES ACT OF 1933

1. The citation for Part 230 continues to read in part as follows:

Authority: 15 U.S.C. 77b, 77f, 77g, 77h, 77j, 77r, 77s, 77sss, 78c, 78d, 78l, 78m, 78n, 78o, 78w, 78*ll*(d), 79t, 80a–8, 80a–24, 80a–29, 80a–30, and 80a–37, unless otherwise noted.

* * * * *

§ 230.502 [Amended]

2. By amending the introductory text of paragraph (d) of § 230.502 by revising the words ''Except as provided in § 230.504(b)(1), securities'' to read ''Securities''.

3. By revising § 230.504(b)(1) to read as follows:

§ 230.504 Exemption for limited offerings and sales of securities not exceeding $1,000,000.

* * * * *

(b) *Conditions to be met.*—(1) *General conditions.* To qualify for exemption under this § 230.504, offers and sales must satisfy the terms and conditions of §§ 230.501 and 230.502(a) and (d).

* * * * *

Dated: May 21, 1998.

By the Commission.

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 98–14024 Filed 5–27–98; 8:45 am]

BILLING CODE 8010–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Parts 809 and 864

[Docket No. 97N–0135]

Medical Devices; Hematology and Pathology Devices; Reclassification; Restricted Devices; OTC Test Sample Collection Systems for Drugs of Abuse Testing; Public Hearing

AGENCY: Food and Drug Administration, HHS.

ACTION: Notification of public hearing on proposed rule.

SUMMARY: The Food and Drug Administration (FDA) is announcing a public hearing on a proposed rule to reclassify over-the-counter (OTC) test sample collection systems for drugs of abuse testing. The purpose of the public hearing is to solicit input on the proposed rule in addition to comments being submitted to the docket. The information obtained at the hearing will assist FDA in its preparation of a final rule.

DATES: The public hearing will be held on June 19, 1998, from 9 a.m. to 5 p.m. Written notices of participation should be filed by June 8, 1998. Submit written comments by July 5, 1998.

ADDRESSES: The public hearing will be held at the Food and Drug Administration, 5600 Fishers Lane, conference rooms D and E, Rockville, MD 20857. Submit written notices of participation and written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Steven I. Gutman, Center for Devices and Radiological Health (HFZ–440), Food and Drug Administration, 2098 Gaither Rd., Rockville, MD 20850, 301–594–3084.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of March 5, 1998 (63 FR 10792), FDA published a proposed rule to reclassify OTC test sample collection systems for drugs of abuse testing. FDA has determined that a public hearing on the proposed rule is warranted. The hearing will be directed by William B. Schultz, Deputy Commissioner for Policy, FDA. To the extent possible, oral testimony should address the issues identified in the proposed rule (63 FR 10792). The procedures governing the hearing are those applicable to a public hearing before the Commissioner of Food and Drugs under 21 CFR part 15.

Interested persons who wish to participate may, on or before June 8, 1998, submit a notice of participation to the Dockets Management Branch (address above). All notices submitted should be identified with the docket number found in brackets in the heading of this document and should contain the name, address, telephone number, business affiliation of the person requesting to make a presentation, a brief summary of the presentation, and the approximate time requested for the presentation.

Individuals or groups having similar interests are requested to consolidate their comments and present them through a single representative. FDA will allocate the time available for the hearing among the persons who properly file a notice of appearance.

After reviewing the notice of participation and accompanying information, FDA will schedule each appearance and notify each participant by mail or telephone of the time allotted to the person and the approximate time the person's presentation is scheduled to begin. FDA may require joint presentations by persons with common interests. The schedule of the public hearing will be available at the hearing and it will be placed on file in the Dockets Management Branch following the hearing.

The administrative record of the proposed regulation will be open for 15 days after the hearing to allow comments on matters raised at the hearing. Persons who wish to provide additional materials for consideration are to file these materials with the Dockets Management Branch (address above) during that period.

The hearing is informal, and the rules of evidence do not apply. No participant may interrupt the presentation of another participant. Only the presiding officers and panel members may question any person during or at the conclusion of their presentation.

Dated: May 20, 1998.

William K. Hubbard,

Associate Commissioner for Policy Coordination.

[FR Doc. 98–14048 Filed 5–27–98; 8:45 am]

BILLING CODE 4160–01–F

DEPARTMENT OF THE INTERIOR

Office of Surface Mining Reclamation and Enforcement

30 CFR Part 936

[SPATS No. OK–022–FOR]

Oklahoma Regulatory Program

AGENCY: Office of Surface Mining Reclamation and Enforcement (OSM), Interior.

ACTION: Proposed Rule; reopening and extension of public comment period on proposed amendment.

SUMMARY: OSM is announcing receipt of revisions and additional explanatory information pertaining to a previously proposed amendment to the Oklahoma regulatory program (hereinafter referred to as the ''Oklahoma program'') under the Surface Mining Control and Reclamation Act of 1977 (SMCRA). The revisions and additional explanatory information pertain to normal